Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program.

Dabelea D, Ma Y, Knowler WC, Marcovina S, Saudek CD, Arakaki R, White NH, Kahn SE, Orchard TJ, Goldberg R, Palmer J, Hamman RF; Diabetes Prevention Program Research Group.

Diabet Med. 2014 Sep;31(9):1064-8. doi: 10.1111/dme.12437. Epub 2014 Apr 9.

2.

Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program.

Walford GA, Ma Y, Christophi CA, Goldberg RB, Jarolim P, Horton E, Mather KJ, Barrett-Connor E, Davis J, Florez JC, Wang TJ; Diabetes Prevention Program Research Group.

Diabetologia. 2014 May;57(5):935-9. doi: 10.1007/s00125-014-3183-2. Epub 2014 Feb 20.

3.

Short and long-term lifestyle coaching approaches used to address diverse participant barriers to weight loss and physical activity adherence.

Venditti EM, Wylie-Rosett J, Delahanty LM, Mele L, Hoskin MA, Edelstein SL; Diabetes Prevention Program Research Group.

Int J Behav Nutr Phys Act. 2014 Feb 12;11:16. doi: 10.1186/1479-5868-11-16.

4.

Common variation at PPARGC1A/B and change in body composition and metabolic traits following preventive interventions: the Diabetes Prevention Program.

Franks PW, Christophi CA, Jablonski KA, Billings LK, Delahanty LM, Horton ES, Knowler WC, Florez JC; Diabetes Prevention Program Research Group.

Diabetologia. 2014 Mar;57(3):485-90. doi: 10.1007/s00125-013-3133-4. Epub 2013 Dec 7.

5.

Confirming glycemic status in the Diabetes Prevention Program: implications for diagnosing diabetes in high risk adults.

Christophi CA, Resnick HE, Ratner RE, Temprosa M, Fowler S, Knowler WC, Shamoon H, Barrett-Connor E, Kahn SE; Diabetes Prevention Program Research Group.

J Diabetes Complications. 2013 Mar-Apr;27(2):150-7. doi: 10.1016/j.jdiacomp.2012.09.012. Epub 2012 Nov 7.

6.

Signal transduction and modulating pathways in tryptamine-evoked vasopressor responses of the rat isolated perfused mesenteric bed.

Anwar MA, Ford WR, Herbert AA, Broadley KJ.

Vascul Pharmacol. 2013 Jan;58(1-2):140-9. doi: 10.1016/j.vph.2012.10.007. Epub 2012 Oct 30.

7.

Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program.

Florez JC, Jablonski KA, McAteer JB, Franks PW, Mason CC, Mather K, Horton E, Goldberg R, Dabelea D, Kahn SE, Arakaki RF, Shuldiner AR, Knowler WC; Diabetes Prevention Program Research Group.

PLoS One. 2012;7(9):e44424. doi: 10.1371/journal.pone.0044424. Epub 2012 Sep 11.

8.

Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: the Diabetes Prevention Program.

Pollin TI, Isakova T, Jablonski KA, de Bakker PI, Taylor A, McAteer J, Pan Q, Horton ES, Delahanty LM, Altshuler D, Shuldiner AR, Goldberg RB, Florez JC, Franks PW; Diabetes Prevention Program Research Group.

PLoS Genet. 2012;8(8):e1002895. Epub 2012 Aug 30.

9.

Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program.

Delahanty LM, Pan Q, Jablonski KA, Watson KE, McCaffery JM, Shuldiner A, Kahn SE, Knowler WC, Florez JC, Franks PW; Diabetes Prevention Program Research Group.

Diabetes Care. 2012 Feb;35(2):363-6. doi: 10.2337/dc11-1328. Epub 2011 Dec 16.

10.

Vasoconstrictor and vasodilator responses to tryptamine of rat-isolated perfused mesentery: comparison with tyramine and β-phenylethylamine.

Anwar MA, Ford WR, Broadley KJ, Herbert AA.

Br J Pharmacol. 2012 Apr;165(7):2191-202. doi: 10.1111/j.1476-5381.2011.01706.x.

11.

TCF7L2 polymorphism, weight loss and proinsulin:insulin ratio in the diabetes prevention program.

McCaffery JM, Jablonski KA, Franks PW, Dagogo-Jack S, Wing RR, Knowler WC, Delahanty L, Dabelea D, Hamman R, Shuldiner AR, Florez JC; Diabetes Prevention Program Research Group.

PLoS One. 2011;6(7):e21518. doi: 10.1371/journal.pone.0021518. Epub 2011 Jul 26.

12.

Menopause and risk of diabetes in the Diabetes Prevention Program.

Kim C, Edelstein SL, Crandall JP, Dabelea D, Kitabchi AE, Hamman RF, Montez MG, Perreault L, Foulkes MA, Barrett-Connor E; Diabetes Prevention Program Research Group.

Menopause. 2011 Aug;18(8):857-68. doi: 10.1097/gme.0b013e31820f62d0.

13.

Effects of dietary amines on the gut and its vasculature.

Broadley KJ, Akhtar Anwar M, Herbert AA, Fehler M, Jones EM, Davies WE, Kidd EJ, Ford WR.

Br J Nutr. 2009 Jun;101(11):1645-52. doi: 10.1017/S0007114508123431. Epub 2008 Nov 19.

PMID:
19017420
14.

First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes.

Venditti EM, Bray GA, Carrion-Petersen ML, Delahanty LM, Edelstein SL, Hamman RF, Hoskin MA, Knowler WC, Ma Y; Diabetes Prevention Program Research Group.

Int J Obes (Lond). 2008 Oct;32(10):1537-44. doi: 10.1038/ijo.2008.134. Epub 2008 Aug 19. Erratum in: Int J Obes (Lond). 2009 Jan;33(1):182.

15.

Dietary trace amine-dependent vasoconstriction in porcine coronary artery.

Herbert AA, Kidd EJ, Broadley KJ.

Br J Pharmacol. 2008 Oct;155(4):525-34. doi: 10.1038/bjp.2008.286. Epub 2008 Jul 7.

16.

Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program.

Moore AF, Jablonski KA, McAteer JB, Saxena R, Pollin TI, Franks PW, Hanson RL, Shuldiner AR, Knowler WC, Altshuler D, Florez JC; Diabetes Prevention Program Research Group.

Diabetes. 2008 Sep;57(9):2503-10. doi: 10.2337/db08-0284. Epub 2008 Jun 10.

17.

Vasoconstriction of porcine left anterior descending coronary artery by ecstasy and cathinone is not an indirect sympathomimetic effect.

Baker KE, Herbert AA, Broadley KJ.

Vascul Pharmacol. 2007 Jul;47(1):10-7. Epub 2007 Mar 19.

PMID:
17459782
18.

Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study.

Shalita AR, Chalker DK, Griffith RF, Herbert AA, Hickman JG, Maloney JM, Miller BH, Tschen EH, Chandraratna RA, Gibson JR, Lew-Kaya DA, Lue JC, Sefton J.

Cutis. 1999 Jun;63(6):349-54.

PMID:
10388959
19.

CHILD syndrome: lack of expression of epidermal differentiation markers in lesional ichthyotic skin.

Dale BA, Kimball JR, Fleckman P, Herbert AA, Holbrook KA.

J Invest Dermatol. 1992 Apr;98(4):442-9.

20.

Supplemental Content

Loading ...
Support Center